Post by AIM INTELLIX GLOBAL SERVICES Pvt. Ltd.

🚨 New Regulatory Update – Egypt EDA (2026) The Egyptian Drug Authority (EDA) has released a new guidance document outlining the required CTD sections for Human Pharmaceutical Variation submissions. 📌 Key highlights: ✅ Clear CTD requirements for both Drug Substance (S Part) and Drug Product (P Part) variations. ✅ Covers changes related to API manufacturers, manufacturing sites, analytical methods, specifications, packaging, stability, batch size, shelf life, and more. ✅ Helps applicants prepare complete variation dossiers, reducing regulatory queries and review delays. For Regulatory Affairs, CMC, and Pharmaceutical Development teams, this guidance is a valuable reference to improve submission quality and ensure compliance with EDA expectations. Staying updated with evolving regulatory requirements is essential for faster approvals and successful lifecycle management. #RegulatoryAffairs #Pharmaceuticals #CTD #CMC #Variations #EgyptEDA #DrugRegistration #LifecycleManagement #Quality #PharmaCompliance